Akorn and Cipla Announce the Signing of an Exclusive Drug Development and Supply Agreement for an Injectable ANDA Drug Product for the Prevention of Organ Transplant Rejection

Akorn today announced the signing of an exclusive drug development and supply agreement with Cipla, a leading Indian pharmaceutical company located in Mumbai, India, for an injectable ANDA drug product for the prevention of organ transplant rejection. In June 2007, Akorn previously announced the exclusive agreement for the oral dosage form of this drug product. The addition of the injectable format expands the breadth of Akorn's offerings for this indication.
Business Wire Via Yahoo! Finance